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Purpose: To optimize and formulate promethazine theoclate fast-dissolving tablets that offer a suitable 
approach to the treatment of nausea and vomiting. 
Method: The solubility of promethazine theoclate was increased by formulating it as a fast-dissolving 
tablet containing β-cyclodextrin, crospovidone, and camphor, using direct compression method. A 3
3
 full 
factorial design was used to investigate the combined influence of three independent variables - 
amounts of camphor, crospovidone and β-cyclodextrin - on disintegration time, friability and drug 
release after 5 min.  
Result: The optimization study, involving multiple regression analysis, revealed that optimum amounts 
of camphor, crospovidone and β-cyclodextrin gave a rapidly disintegrating/dissolving tablet. A 
checkpoint batch was also prepared to verify the validity of the evolved mathematical model. The 
optimized tablet should be prepared with an optimum amount of β-cyclodextrin (3.0 mg), camphor (3.29 
mg) and crospovidone (2.61 mg) which disintegrated in 30 s, with a friability of 0.60 % and drug release 
of 89 % in 5 min.  
Conclusion: The optimized approach aided both the formulation of fast-dissolving theoclate tablets and 
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INTRODUCTION 
 
Retention of an administered antiemetic oral 
dose and its subsequent absorption during 
therapy is critically affected by recurrent 
emesis, a process coordinated by the 
vomiting centre in the lateral reticular 
formation of the medulla receiving inputs from 
the chemoreceptor trigger zone and other 
neural sites [1]. Vomiting induced by 
physiological processes such as impaired 
gastric emptying and other gastric 
disturbances will also affect drug retention 
and absorption [2]. Retention of oral dose is, 
therefore, a prerequisite for absorption to 
prevent emesis. For drug with low 
bioavailability, partial drug loss by emesis will 
result in therapeutic failure. One such 
antiemetic drug, promethazine theoclate, 
after oral dosing, undergoes extensive gastric 
and first pass effect. This results in low 
bioavailability which, therefore, will not 
minimize the rate of vomiting [3].
 
 
A fast dissolving system can be defined as a 
dosage form for oral administration, which 
when placed in the mouth, rapidly disperses 
or dissolves and can be swallowed in the 
form of liquid [4]. Fast-dissolving tablets of 
promethazine theoclate are designed for 
rapid and complete absorption in the 
gastrointestinal tract in order to achieve 
therapeutic success. Fast-dissolving 
formulations are popular because they are 
easy to administer and lead to improved 
patient compliance. Paediatric and geriatric 
patients have difficulty swallowing 
(dysphasia) conventional dosage forms [5]. 
Fast-dissolving drug delivery systems may 
offer a solution to this problem. This dosage 
form dissolves or disintegrates in the oral 
cavity within a minute without the need of 
water or chewing [6].
 
The basic approach to the development of 
fast dissolving tablets (FDT) is the use of 
superdisintegrants. Another approach is 
maximizing the pore structure of the tablets. 
Freeze-drying [7,8] and vacuum-drying [9,10] 
techniques have been tried by researchers to 
maximize the pore structure of the tablet 
matrix. Freeze drying is cumbersome and 
yields a fragile and hygroscopic product. 
Therefore, the vacuum-drying technique was 
adopted in the present study.  
 
Full factorial experimental design is one of 
the best tools for studying the effect of 
different variables on the quality determinant 
parameters of any formulation. Multiple 
regression analysis of results gives an 
equation that adequately describes the 
influence of the independent formulation 
variables on the selected responses [11].  
 
The objective of the present work was to 
develop fast dissolving tablets of 
promethazine theoclate based on a small 
number of experimental runs [12]. Use of a 3
3
 
factorial design was attempted to generate an 
optimized region in the contour plots where 
the combination of β-cyclodextrin (solubility 
enhancer), camphor (pore forming agent) and 
crospovidone (superdisintegrant) could 
provide hard and rapid disintegrating tablets 
which can release the drug maximally within 






Promethazine theoclate and crospovidone 
were gifts from Mehta Pharmaceuticals, 
Mumbai, India and BASF Chemicals, Mount 
Olive, NJ, USA, respectively. β-cyclodextrin, 
Lactopress
®
 (lactose anhydrate) and 
microcrystalline cellulose (Avice PH102) were 
also obtained as gifts from Signet Chemicals, 
Mumbai, India. Camphor, mannitol, talc and 
magnesium stearate were purchased from 
Ranbaxy Chemicals, India). All other 




 response surface model factorial 
design 
 
The traditional approach to developing a 
formulation is to change one variable at a 
time. By this method it is difficult to develop 
an optimized formulation, as the method 
reveals nothing about the interactions among 
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the variables. Hence, a response surface 
design model with 3 factors, 3 levels, and 27 
runs was selected for the optimization study. 
A 3
3
 randomized full factorial design was 
used in the present study. In this design, 3 
formulation independent factors are 
evaluated, each at 3 levels (low, medium and 
high), and experimental trials are performed 
at all 27 possible combinations. The amount 
of subliming agent, camphor (X1), the amount 
of superdisintegrant, crospovidone (X2), and 
the amount of solubility enhancer, β-
cyclodextrin (X3) were selected as 
independent variables. The disintegration 
time (DT), percentage friability (% F) and 
drug release in five minute (Q5) were selected 
as dependent variables. After application of 
full factorial design and with the aid of 
produced polynomial terms, the amount of 
three formulation variables was optimized. 
The optimized amount of the camphor, 
crospovidone and β-cyclodextrin were 
incorporated in the tablet which was used as 
the check point of the regression analysis 
model. The polynomial equation generated 
by this experimental design (using Design 
Expert 7.1.6 software, State Ease Inc) is as 
follows: 
 
Y= b0 + b1X1 + b2X2 + b3X3 + b12X1 X2 + b13X1 X3 + 
b23X2 X3 + b11X1 X1 + b22X2 X2 + b33X3 X3  ……     (1)
 
 
where Y is the dependent variable; b0 is the 
intercept; b1 to b33 are the regression 
coefficients; and X1, X2 and X3 are the 
independent formulation variables [12].
 
 
Preparation of promethazine theoclate 
tablets 
 
The composition of the preliminary and 
factorial design batches are shown in Tables 
1 and 2, respectively. All the raw materials 
were passed through a screen of 450 µm 
aperture size prior to mixing. Promethazine 
theoclate, camphor, crospovidone, 
microcrystalline cellulose, mannitol and 
lactose were mixed dry using a glass mortar 
and pestle. The blends were lubricated with 2 
%w/w each of talc and magnesium stearate. 
The blends were compressed in a single-
punch tablet machine (Cadmach, 
Ahmedabad, India) to approx. 100 mg 
convex-faced tablets with a diameter of 5 
mm. The tablets were dried for 6 h under 
vacuum (30 Kpa) at 50 
o
C to render the 
tablets porous by sublimation of the camphor.  
 
Evaluation of tablet properties 
 
The crushing strength of the tablets was 
measured using a Monsanto hardness tester 
while tablet friability was assessed with a 
Roche friabilator. Twenty pre-weighed tablets 
were rotated at 25 rpm for 4 min and then re-
weighed after removal of fines (using 250 µm 
aperture screen), and the weight loss (%) 
was calculated. The wetting time of the 
tablets was determined using a simple 
procedure [13]. Five circular pieces of tissue 
paper (10 cm diameter, 0.45 µm pore size, 
Hi-media Corp) were placed in a 10 cm 
diameter Petri dish. Ten millilitres of water 
containing a water-soluble dye, eosin (0.01 
%), was added to the Petri dish. A tablet was 
carefully placed on the surface of the tissue 
paper. The time required for water to reach 
the upper surface of the tablets was noted as 
the wetting time [14].  
 
A modified method was used to determine 
the disintegration time and dissolution profile 
of the tablets to simulate conditions in the 
oral cavity. To assess disintegration time, 6 
ml of Sorenson’s buffer (pH 6.8) at 37 ± 0.5 
0
C was placed inside a 10 ml cylindrical glass 
vessel in such a way that 2 ml of the media 
was below the sieve and 4 ml above the 
sieve. One tablet was placed on the sieve 
and the whole assembly was then mounted 
on a high precision water bath  shaker 
(Narang Scientific Works, India). The time 
taken for all the particles to pass through the 
sieve was noted as the disintegration time of 
the tablet. Six tablets, selected randomly from 
each batch, were tested and the mean value 
was calculated [15]. To determine dissolution 
profile, the apparatus employed for 
disintegration test was also used. Samples (1 
ml) were withdrawn at different time intervals 
and replaced with fresh medium. The 
samples were filtered, diluted with  
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Table 1: Preparation and evaluation of preliminary trial batches (n = 6) 
 
Ingredient T1 T2 T3 T4 T5 T6 T7 T8 
Promethazine 
theoclate (mg) 
20 20 20 20 20 20 20 20 
Camphor (mg) 2.5 5 - - 2.5 5 5 5 
Crospovidone (mg) - - 1 3 1 3 3 3 
β-cyclodextrin (mg) - - - - - - 10 20 
Avicel PH102 (mg) 33.5 31 35 33 32.5 28 18 8 
Lactopress
®
 (mg) 25 25 25 25 25 25 25 25 
Mannitol (mg) 15 15 15 15 15 15 15 15 
Talc (mg) 2 2 2 2 2 2 2 2 
 
Table 2: Some physicochemical parameters of the tablet formulations  
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Table 2: Some physicochemical parameters of the tablet formulations (±SD, n = 6)  
 
Parameter T1 T2 T3 T4 T5 T6 T7 T8 
HD (kg/cm
2
) 3.2±0.1 3.3±0.1 2.7±0.2 2.4±0.3 3.1±0.1 3.0±0.2 3.3±0.1 3.5±0.3 
Friability (%) 0.6±0.0 1.1±0.2 0.6±0.0 0.5±0.1 0.5±0.0 0.7±0.0 0.7±0.1 0.7±0.1 
DT (s) 105±3 82±2 96±5 79±6 80±1 27±5 23±2 21±3 
WT (s) 99±1 75±3 84±2 64±4 71±5 19±4 17±2 13±3 
Q5 (%) 29±2 33±3 31±3 34±5 32±5 38±1 59±3 93.1±5.2 
 
HD = hardness; DT = disintegration time; WT = wetting time; Q5 = drug release in 5 min  
 
Sorenson’s buffer (pH 6.8) and analyzed 




A response surface model factorial design 
with 3 independent formulation variables at 3 
different levels were used to study the effects 
on dependent variables. All the batches of 
fast dissolving tablets were statistically (p < 
0.05) evaluated with regard to disintegration 
time, friability and drug release by using 
software Design Expert version 7.1.6 (State 




The results, shown in Table 2, indicate that 
concentration-dependent disintegration was 
observed in all batches prepared using 
camphor as a subliming agent (T1 and T2) 
and crospovidone as superdisintegrant (T3 
and T4). Tablets containing combinations of 
subliming agent and superdisintegrant (T5 
and T6) showed the least disintegration time. 
Sharma et al 
Trop J Pharm Res, October 2010; 9 (5): 493 
The effect of β-cyclodextrin was obvious; as 
the amount of β-cyclodextrin increased (T6, 
T7 and T8), the release rate of the drug also 
increased 2- to 3-fold.  
 
A factorial design was employed in order to 
systematically investigate the factors 
affecting the formulation and optimize the fast 
dissolving tablet for a disintegration time of 
30 s, friability of < 0.6 %, and drug release of 
up to 90 %.  The transformed values for all 
the batches along with their results are 
shown in Tables 3 and 4.  
 
 
Table 3: Factorial design for formulation batches (±SD, n = 6) 
 
 
Y1 Y2 Y3 Tablet 
code 
X1 X2 X3 
DT (s) F (%) (Q5) 
T1 -1 -1 -1 80.1±3.9 0.545±0.038 32.11±2.62 
T2 -1 0 -1 55.6±4.1 0.421±0.043 34.01±3.26 
T3 -1 1 -1 34.2±5.1 0.321±0.078 35.27±2.60 
T4 0 -1 -1 66.5±4.4 0.801±0.065 36.77±1.30 
T5 0 0 -1 42.1±3.9 0.732±0.025 37.05±1.60 
T6 0 1 -1 27.2±4.9 0.696±0.003 38.40±1.29 
T7 1 -1 -1 55.3±3.9 0.967±0.147 39.11±1.71 
T8 1 0 -1 32.1±3.7 0.878±0.014 40.79±2.08 
T9 1 1 -1 18.6±3.2 0.802±0.023 42.08±2.06 
T10 -1 -1 0 78.5±3.0 0.568±0.034 53.11±2.73 
T11 -1 0 0 51.3±3.9 0.427±0.090 55.34±3.51 
T12 -1 1 0 30.9±3.9 0.339±0.158 57.01±4.04 
T13 0 -1 0 64.1±2.9 0.815±0.081 56.98±1.71 
T14 0 0 0 41.1±1.8 0.764±0.121 58.18±3.73 
T15 0 1 0 23.8±1.8 0.687±0.112 59.30±2.51 
T16 1 -1 0 52.4±2.2 0.972±0.079 60.78±1.85 
T17 1 0 0 30.6±2.0 0.888±0.015 61.21±2.85 
T18 1 1 0 16.1±2.5 0.826±0.080 63.40±1.05 
T19 -1 -1 1 75.4±2.7 0.589±0.077 80.41±3.07 
T20 -1 0 1 50.2±2.7 0.435±0.082 81.98±2.06 
T21 -1 1 1 27.5±2.6 0.345±0.076 83.41±2.58 
T22 0 -1 1 60.4±2.1 0.829±0.073 86.11±3.11 
T23 0 0 1 39.3±3.7 0.772±0.151 90.12±4.00 
T24 0 1 1 21.6±2.7 0.693±0.086 93.13±5.25 
T25 1 -1 1 49.3±3.7 0.984±0.129 92.10±4.02 
T26 1 0 1 28.9±3.3 0.896±0.097 95.13±5.12 
T27 1 1 1 12.1±2.6 0.851±0.073 97.51±3.19 
 
PMT -0.41  0.61 1 30 0.599 88.130 
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Low (-1) Medium (0) High (1) 
X1 (Camphor) 2.5 5 7.5 
X2 (Crospovidone) 1 2 3 
X3 (β-Cyclodextrin) 0 10 20 
 
 
The dependent variables (disintegration time, 
DT; friability, F; and drug release, Q5) 
obtained at various levels of the 3 
independent variables (X1, X2, and X3) was 
subjected to multiple regression to yield a 
second-order polynomial equation. The 
coefficient values obtained are shown in 
Table 5. 
 
Among the 3 independent variables, 
regression analysis indicate that coefficients 
b13, b23, b11, and b33 for DT; b13, b23, b22 and 
b33 for F, and b12, b23, b11, and b22 for Q5 (p ≤ 
0.05) were insignificant in predicting DT, F, 
and Q5. Hence, these terms were omitted 
from the full model to obtain a reduced 
second-order polynomial equation by multiple 
regression of DT, F, and Q5 and the 




The value of the correlation coefficient (R
2
) of 
the polynomial regression equation was 
greater than 0.99, which is near to 1, thus 
indicating a good fit for all the dependent 
variables. The results of analysis of variance 
(ANOVA) are shown in Table 6. The DT, F, 
and Q5 values measured for the various 
batches showed wide variations. The results 
indicate that DT, F, and Q5 data were strongly 
affected by the variables selected for the 
study.  
 
Table 5: Regression analysis data 
 
Disinteg time (min) Friability (%) Drug release (%) Response 
 FM* RM** FM RM FM RM 
b0 40.666667 40.88889 0.747333 0.754333 58.66804 58.373 
b1 -10.444444 -10.4444 0.226333 0.226333 4.4145 4.4145 
b2 -20.611111 -20.6111 -0.08389 -0.08389 1.778722 1.778722 
b3 -2.666667 -2.66667 0.012833 0.012833 25.79467 25.79467 
b12 2.666667 2.666667 0.021083 0.021083 0.077917 - 
b13 0.083333 - 0.000167 - 1.52975 1.52975 
b23 -0.166667 - -0.00158 - 0.637833 - 
b11 0.333333 - -0.08467 -0.08467 -0.40761 - 
b22 2.833333 2.833333 0.011333 - -0.03494 - 
b33 0.000000 - -0.00083 - 4.714222 4.714222 
 
*FM Full Model; **RM = Reduced Model (p < 0.05). 
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Table 6: Results of ANOVA of full models and reduced model for dependent variables 
 
For disintegration time 
Full Model df SS MS f R
2 
Regression 9 9872.861 1096.984 1047.355 0.9981 
Residual 17 17.805 1.047   
Reduced Model      
Regression 5 9871.778 1974.356 2195.019 0.9980 
Residual 21 18.888 0.899   
For friability 
Full Model  df SS MS f R
2 
Regression 9 1.100 0.122 323.798 0.9942 
Residual 17 0.006 0.0003   
Reduced Model      
Regression 5 1.100 0.220 639.289 0.9936 
Residual 21 0.007 0.0003   
For drug release 
Full Model df SS MS f R
2 
Regression 9 12551.68 1394.631 1124.424 0.9983 
Residual 17 21.085 1.240   
Reduced Model      
Regression 5 12545.72 2509.144 1948.363 0.9978 
Residual 21 27.044 1.287   
 
df = degrees of freedom; SS = sum of squares; MS = mean of squares; f = Fischer's ratio; R
2 
= regression coefficient.  
 
The main effects of X1, X2, and X3 represent 
the average result of changing one variable 
at a time from its low to high level. The 
interaction terms (X1X2, X1X3, X2X3, X1X1, 
X2X2, and X3X3) show how the DT, F, and Q5 
changes when two variables are 
simultaneously changed. The negative 
coefficients for all 3 independent variables 
(X1, X2, and X3) indicate a favourable effect on 
the disintegration time, while the positive 
coefficients for the interactions between 2 
variables (X1X2, X1X3, X1X1, X2X2, and X3X3) 
indicate an unfavorable effect on the 
disintegration time. The positive coefficients 
(X1 and X3) for the independent variables 
show an unfavourable effect on friability, 
while the negative coefficients for the 
interactions between 2 variables (X2X3, X3X3, 
and X1X1) imply a favourable effect on the 
parameter (friability). The positive coefficients 
for independent variables (X1, X2 and X3) point 
to a favorable effect on Q5, but the negative 
coefficients for the interactions between two 
variables (X1X1 and X2X2) indicate an 




Combinational effect on disintegration 
time  
 
The results of multiple linear regression 
analysis (full model) reveal that on increasing 
the amount of either camphor or 
crospovidone, a decrease in disintegration 
time was observed. When a higher amount of 
camphor was used, higher porosity was 
expected for the tablets. Due to the porous 
network of the tablet, water uptake increased 
and thus disintegration was facilitated. When 
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a higher amount of superdisintegrant 
(crospovidone) was incorporated, wicking 
was enhanced, leading to a decrease in the 
disintegration time of the tablets. Addition of 
β-cyclodextrin might have enhanced the 
swelling of the tablet due to increase in the 
absorption of the medium. The combined 
effect of porous structure, wicking and 
swelling would have rendered the tablets very 
rapidly disintegrating.  
 
Combinational effect on friability  
 
An increase in the concentration of camphor 
led to an increase in friability because the 
coefficient, b1, bears a positive sign. When a 
higher amount of camphor was used, more 
porous tablets, which showed mechanical 
weakness, were produced. Increase in the 
concentration of crospovidone resulted in 
decreased friability because b2 bears a 
negative sign. Thus, addition of crospovidone 
to the tablet formulation made it less friable. 
Tablets with low friability (≤ 0.6 %) may not 
break during handling, packaging and/or 
shipping [15]. Crospovidone is known to 
produce mechanically strong fast-dissolving 
tablets [15]. 
 
Combinational effect on drug release  
 
The coefficient, b3, bears a positive sign 
which shows that increase in the 
concentration of β-cyclodextrin would also 
result in a rise in the dissolution of the drug. 
As indicated by the dissolution data for the 
physical mixture of the drug and β-
cyclodextrin, increased wettabilty and 
dispersabilty of the tablets led to 
improvement in drug dissolution. The effect of 
β-cyclodextrin on wettabilty can be attributed 
to the enhanced surface area available for 
dissolution due to reduction in interfacial 
tension between the drug and the dissolution 
medium. During the dissolution studies, it 
was noted that the tablet formulation 
containing β-cyclodextrin sank rapidly, unlike 
the tablets without β-cyclodextrin which 
remained floating on the surface of the 
dissolution medium for a period of time. In 
fact, both the impartation of a porous 
structure to the tablets by camphor and the 
wicking property induced by crospovidone 
are responsible for enhanced drug 
dissolution. The coefficients for drug release, 
b1 and b2, possess a positive sign which 
shows that they also facilitated the dissolution 
of the drug.  
 
Optimization of fast dissolving tablet 
formulation 
 
The optimization of the fast-dissolving tablet 
formulation was targeted to achieve a 
disintegration time (DT) of 30 s, friability of 
0.6 % and drug release of 90 % (at the end of 
5 min). The optimized amounts, obtained with 
the aid of software, are shown in the surface 
response prediction curves in illustrated in 
Figure 1. A checkpoint batch (PMT) was 
prepared at X1 = -0.41 level; X2 = 0.61 level 
and X3 = 1.00 level at which DT was 30 s, 
friability 0.599 % and drug release (in 5 min) 
88.13 %. The desirability of the optimization 
process was 0.989 which is near to unity. 
 
From the full model, it was found that the 
friability of the checkpoint batch, PMT, was 
0.594 ± 0.007 %, disintegration time 
31.00±0.73 s, drug release (at the end of 5 




and wetting time 39 ± 0.09 s. As shown in 
Table 3, the optimized batch, PMT, indicates 
that the results were as expected. Thus, the 
statistical model is mathematically valid. 
Compared with the experimentally optimized 
preparation, the observed responses are in 
close agreement with the predicted values of 
the optimized formulation, thereby 
demonstrating the feasibility of the 
optimization procedure used in developing 





Optimization of fast-dissolving tablet 
formulation of promethazine theoclate using 
3
3
 factorial design was achieved in this study.  
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Figure 1: Response surface prediction plot 
 
The amount of independent formulation 
variables, camphor, crospovidone, and β-
cyclodextrin showed a significant effect on 
disintegration time and friability as well as the 
drug release characteristics of the fast-
dissolving tablets. The experimental design 
provided a better understanding of the effect 
of formulation variables on the quality of fast-
dissolving tablets containing the hydrophobic 
drug. The optimal batch exhibited a 
disintegration time of 31 s, friability of 0.06 % 
and drug release (within 5 min) of 89 %. 
Thus, by adopting a systematic formulation 
approach, an optimum point can be reached 




1. Ward AE. Studies of prochlorperazine as a buccal 
tablet and a oral tablet for the treatment of 
dizziness, nausea and vomiting in a general 
practice setting. The British Journal of Clinical 
Practice 1998; 42(6): 2280-2282. 
2. Thompson DG, Richelson E, Malagelada JR. 
Perturbation of gastric emptying and duodenal 
motility via the central nervous system. 
Gastroenterology 1982; 83: 1200-1206. 
3. Gregory RE, Ettinger DS. HT3 receptor antagonists 
for the prevention of chemotherapy-induced 
nausea and vomiting: a comparison of their 
pharmacology and clinical efficacy. Drugs 
1998; 55: 173–189.  
4. Seager H. Drug delivery products and the zydis fast 
dissolving dosage forms. J Pharm Pharmacol 
1998; 50: 375-382.   
5. Habib W, Khankari R, Hontz J. Fast-dissolving drug 
delivery systems: critical review in 
therapeutics. Drug Carrier Systems 2000; 17: 
61-72. 
6. Bi Y, Sunada H, Yonezawa Y, Dayo K, Otsuka A, 
Iida K. Preparation and evaluation of a 
compressed tablet rapidly disintegrating in oral 
cavity. Chem Pharm Bull (Tokyo) 1996; 44: 
2121-2127. 
7. Corveleyn S, Remon JP. Formulation and 
production of rapidly disintegrating tablets by 
lyophilization using hydrochlorthiazide as a 
model drug. Int J Pharm 1997; 152: 215-225. 
8. Remon JP, Corveleyn S. Freeze-dried rapidly 
disintegrating tablets. US patent 6 010 719, 
January 4, 2000. 
9. Heinemann H, Rothe W. Preparation of porous 
tablets. US patent 3 885 026, May 20, 1975. 
10. Knistch A, Hagen E, Munz HD. Production of 
porous tablets. US patent 4 134 843. January 
16, 1979. 
11. Wehrle P,  Nobelis
 
P, Cuine A,Stamm A. response 
surface methodology: An interesting statistical 
tool for process optimization and validation: 
example of wet granulation in a high-shear 
mixer. Drug Dev Ind Pharm 1993; 19: 1637-
1653. 
12. Bolton S. Pharmaceutical Statistics. New York: 
Marcel Decker Inc.; 1990. 
13. Li S, Lin S, Chien YW, Daggy BP, Mirchandani HL. 
Statistical optimization of gastric floating 
system for oral controlled delivery of calcium. 
AAPS Pharm Sci Tech [serial online] 2001; 2: 
Article 1. 
14. Banker, Gilbert S, Anderson, Neil R. Tablets. In: 
Lachman L.; Lieberman A, Kanig J L, Eds. The 
theory and practice of industrial pharmacy, 3rd 
edn. Philladelphia: Lea and Febiger: 1986. pp 
293-345 
15. Gohel MC, Patel MM, Amin A, Agrawal R, Dave R, 
Bariya N. Formulation design and optimization 
of mouth dissolving tablets of nimuslide using 
vacuum drying technology technique. AAPS 
Pharm Sci Tech 2004; 5: Article 36. 
16. Late SG, Yi-Ying Y, Banga AK. Effect of 
disintegration promoting agent, lubricants and 
moisture treatment on optimized fast 
disintegrating tablets. Int J Pharm 2009; 365: 
4-11. 
 
